BOSTON — Improvement in plaque psoriasis itch and severity, including in intertriginous areas, was significant in patients treated with roflumilast, according to a poster presented at the American Academy of Dermatology Annual Meeting.
“Roflumilast is a nonsteroid, phosphodiesterase-4 inhibitor, so it has a very benign mechanism of action,” Mark G. Lebwohl, MD, dean for clinical therapeutics and chair emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, told Healio. “It is very effective, particularly in